TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29768139
Drug: Canakinumab 300
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 300 mg every 4 weeks
Study: 12730702
Drug: Adequate intake
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate intake of folate, B12, and B6 in doses comparable to or above FDA recommendations
Study: 11201834
Drug: Standard combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combined therapy with nonsteroid antiinflammatory drugs, reducers of trophic processes, physiotherapy
Study: 11201834
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus bioresonance treatment (BRT)
Study: 6342965
Drug: Osmosin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmosin (7 mg indomethacin per hour over a period of approximately 10 hours)
Study: 6342965
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg per day for 4 weeks)
Study: 12296776
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment
Study: 28389075
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1% unbuffered sodium hypochlorite and 15% EDTA solution)
Study: 17726570
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus rosiglitazone
Study: 18693456
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin
Study: 17726570
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus acarbose
Study: 25514302
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg daily)
Study: 22543151
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hepatoprotective drugs only)
Study: 18461096
Drug: Glucose (1
Normalized name: Fludeoxyglucose (18F)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (1 g x kg body mass(‐1))
Study: 26432775
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy (SAP) only
Study: 24490236
Drug: Cue-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue-centered treatment
Study: 30371301
Drug: Exenatide once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide once-weekly
Study: 21434995
Drug: Sitagliptin to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin to exenatide once-weekly
Study: 21434995
Drug: Pioglitazone to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone to exenatide once-weekly
Study: 12741429
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg
Study: 18821092
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg + NETA 1 mg
Study: 27623621
Drug: Nimodipine alone
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine alone (30 mg/time, 3 times daily)
Study: 16285195
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug treatment
Study: 22633824
Drug: REGN727 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN727 150 mg every 2 weeks
Study: 3548345
Drug: Rapid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid regimen (a mixture of regular and Lente insulins twice daily)
Study: 3548345
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (Lente insulin once daily)
Study: 3548345
Drug: Rapid/intravenous regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid/intravenous regimen (the 'rapid' regimen preceded by overnight intravenous infusion of regular insulin)
Study: 30683146
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment (control)
Study: 18422390
Drug: Niacin extended
Normalized name: Niacin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin extended release and simvastatin (NER/S) 2,000/40 mg/day
Study: 14578234
Drug: Serum triglyceride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum triglyceride, HDL cholesterol, and insulin resistance values in 2000
Study: 29855986
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761, 120 mg twice a day
Study: 7794701
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg twice daily
Study: 16398426
Drug: Traditional herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional herbal medicine (CM) therapy
Study: 18184543
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) therapy
Study: 9690725
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m. for 4-8 weeks
Study: 9690725
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g b.d. for 4-8 weeks
Study: 581421
Drug: Oral antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibacterial preparation with phthalylsulfathiazole and neomycin
Study: 581421
Drug: Oral antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibacterial preparation with phthalylsulfathiazole, neomycin, and tetracycline
Study: 581421
Drug: No antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibacterial preparation
Study: 20572888
Drug: Petrolatum containing
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum containing cream (GEHWOL med Schrundensalbe)
Study: 20572888
Drug: Urea 10%
Normalized name: UREA 10% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea 10% cream (GEHWOL med Lipidro‐Crème)
Study: 8503942
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 and vitamin B6 (pyridoxine) administered together
Study: 8503942
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 administered alone
Study: 29178564
Drug: UC-MSC infusion
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC infusion (1 × 10^6 /kg body weight)
Study: 29178564
Drug: UC-MSC infusion
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC infusion
Study: 19841335
Drug: 3-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day course of amoxicillin
Study: 11345650
Drug: Amsalog 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsalog 180 mg/m2 per day for 5 days
Study: 11345650
Drug: Amsalog administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsalog administered via peripheral venous line
Study: 9574945
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (in female subjects)
Study: 20129336
Drug: Third-generation thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation thermal uterine balloon therapy system with postprocedure curettage
Study: 20129336
Drug: Third-generation thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation thermal uterine balloon therapy system without postprocedure curettage
Study: 16619231
Drug: Medium dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose: 2.2 x 10(11) platelets/m(2)
Study: 16619231
Drug: Higher dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose: 4.4 x 10(11) platelets/m(2)
Study: 8006274
Drug: Active nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nitroglycerin patch therapy (0.4 mg/h, 12 h on/off)
Study: 18793563
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg)
Study: 11553256
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.1 microg kg(‐1) min(‐1)
Study: 14665895
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg once daily)
Study: 9732187
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) alfuzosin (5 mg twice daily)
Study: 9732187
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SR alfuzosin and finasteride (5 mg once daily)
Study: 2191978
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg) with captopril
Study: 2191978
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg) alone
Study: 1093503
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide for six months
Study: 1093503
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide plus prednisone for six months
Study: 25464934
Drug: Combination Treatment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Treatment (for non-remitted patients)
Study: 25751116
Drug: Both Treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Treatments
Study: 16642612
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding therapy at Dachangshu (BL 25), Zusanli (ST 36), Shangjuxu (ST 37)
Study: 16642612
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of salicylazosulfapyridine, 4-6 g/day
Study: 7537286
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day
Study: 10073740
Drug: GI198745 (dutasteride)
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GI198745 (dutasteride) above 1 mg daily doses
Study: 7589382
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rhDNase twice daily for 14 days
Study: 7589382
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rhDNase twice daily during the OEP
Study: 16982546
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a central dose of 15 Gy x 3 within 5-8 days
Study: 3533421
Drug: Luteinizing hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone releasing hormone (LHRH) injection
Study: 3533421
Drug: Testosterone injection
Normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injection
Study: 25896747
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) once a week for 12 weeks
Study: 16766543
Drug: Candesartan 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 4-8 mg/day
Study: 6339152
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion with glucose
Study: 25738669
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of valganciclovir therapy
Study: 15562053
Drug: IV tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV tranexamic acid (TA) 15 mg/kg bolus over 30 min followed by IV infusion of 10 mg . kg(‐1) . h(‐1) for 12 h
Study: 15562053
Drug: IV tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV tranexamic acid (TA) similar to TA-long but infusion discontinued 2 h after deflation, followed by oral TA 1 g after 6 and 12 h
Study: 11054523
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment policy (DAD)
Study: 1283143
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy with additional external beam radiotherapy (40 Gy in 10-20 fractions)
Study: 1283143
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Laser therapy + external beam radiotherapy)
Study: 21503180
Drug: Caffeine 5
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5 mg/kg
Study: 6728874
Drug: Ethanol 0.5
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.5 g/kg and Caffeine 5 mg/kg combined
Study: 23292040
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily with itopride 50 mg three times daily
Study: 1984215
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin (PG) E2 gel
Study: 1984215
Drug: Double balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double balloon device with PGE2 gel
Study: 1984215
Drug: Double balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double balloon device with placebo gel
Study: 6337609
Drug: mianserin 60
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 60 mg nocte
Study: 6337609
Drug: nomifensine 150
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nomifensine 150 mg daily
Study: 27142674
Drug: Intensity Modulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulation Radiation Therapy (IMRT)
Study: 25372582
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day and 40 mg/day combined
Study: 20473044
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg/d
Study: 16480165
Drug: Reduced, escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced, escalating dose (one to three needle) protocol
Study: 16480165
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with spirituality-focused group therapy
Study: 16480165
Drug: Acupuncture without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture without spirituality-focused group therapy
Study: 3202925
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (mean serum ethanol 35 mmol/l)
Study: 3202925
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (serum ethanol 21 mmol/l)
Study: 27993588
Drug: Verum-focused extracorporeal
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum-focused extracorporeal shock wave therapy (energy flux density, .06‐.09mJ/mm2; pulse ratio per point, 200)
Study: 31774125
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH)
Study: 15577058
Drug: PTH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH and anti-resorptive agents (concurrent or sequential therapies)
Study: 3279757
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g amoxycillin suspension twice a day for 8 days
Study: 16450662
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ZOL every two weeks
Study: 16450662
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ZOL every four weeks
Study: 2333541
Drug: Premedicated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedicated with intramuscular atropine 0.015 mg/kg
Study: 12224691
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroids with orally administered prednisone (group A)
Study: 8907140
Drug: morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine sulfate solution or controlled‐release morphine tablets
Study: 8907140
Drug: morphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine administration
Study: 6849724
Drug: Chlormethiazole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole (mean 6.0 mg kg‐1)
Study: 6849724
Drug: Thiopentone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (mean 4.5 mg kg‐1)
Study: 27569824
Drug: L-carnitine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (6 g/L)
Study: 31393619
Drug: L-carnitine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (12 g/L)
Study: 9541124
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of [14C]-palmitate for 60 min (study A)
Study: 9541124
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of [14C]-palmitate for 60 min (study A) and 10 min (study B)
Study: 2667597
Drug: Nicardipine 40
Normalized name: niCARdipine 40 mg/200 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 40 mg
Study: 22114900
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg/ml
Study: 9291287
Drug: Local nasal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nasal immunotherapy (LNIT) with extracts in powder, administered pre-seasonally.
Study: 12444376
Drug: Prophylactic injection
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic injection therapy with 1% aethoxysclerol (group-1)
Study: 12444376
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment without perendoscopic therapy (group-2)
Study: 2240672
Drug: Midazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.75 mg.kg-1 po and atropine 0.03 mg.kg-1 po
Study: 23375025
Drug: Rilonacept 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept 320 mg SC plus indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days
Study: 23375025
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days
Study: 23375025
Drug: Rilonacept 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept 320 mg SC plus oral placebo
Study: 17004672
Drug: Supplemental reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental reading intervention daily for 50 minutes in small groups from October to April
Study: 15005325
Drug: Plastic tanks
Normalized name: plastic IUD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plastic tanks filled with water, saline, and ferric solutions for calibration purposes.
Study: 9472058
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mgI/ml
Study: 30696306
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of indomethacin and nifedipine
Study: 29420695
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily
Study: 29420695
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet twice weekly with a postsex dose (time‐driven)
Study: 29420695
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet before and after sex (event‐driven)
Study: 29420695
Drug: Daily arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily arm
Study: 17003293
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin discontinued during exercise
Study: 9282234
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled ipratropium bromide (total dose of 144 micrograms)
Study: 8102213
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol 4 mg after placebo
Study: 8102213
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 4 mg after placebo
Study: 8102213
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol 4 mg after atenolol
Study: 15063959
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution misoprostol 400 microg
Study: 15063959
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet misoprostol 400 microg
Study: 20043525
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol 400 microg